10Y annualized return is
positive but below market average
at 7.1% per year
TECH has met or exceeded earnings expectations in
few
recent quarters (4/10)
High Gross Profit Margin
High Current Ratio
High Price to Earnings Ratio
High EV/EBITDA Ratio
Get access to all key takeaways, detailed financial metrics, and comprehensive stock analysis with our premium subscription.
Already have an account? Sign in
Overall, Bio-Techne demonstrates solid business quality with strong revenue growth and a diverse product portfolio. However, its reliance on large orders and challenges in specific markets like China present risks. Future prospects appear positive with expectations for market recovery and continued innovation, although economic uncertainties could pose challenges.
Analysis Date: February 5, 2025
Last Updated: May 29, 2025
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
Bio-Techne Corporation is a company that makes tools and products used in scientific research and medical testing. They provide important materials, like proteins and tests, that help scientists study diseases and develop new medicines. Their products are used in labs around the world to help with diagnosing and understanding health issues. In simple terms, Bio-Techne helps researchers and doctors get the information they need to improve health and medicine.
Streams of revenue
Geographic Distribution
Core Products
Business Type
Business to Business
Competitive Advantages
Discover all competitive advantages and strategic moats that protect TECH's market position.
View Premium AnalysisKey Business Risks
Get comprehensive insight into all key business risks that could impact TECH's performance.
Access Full Risk AnalysisLatest News
Partnership Extends Cycurion's Sales Presence Into 135 Countries via LSV's Strategic Partnership with Nokia Partnership Extends Cycurion's Sales Prese...
Antwerp, April 22, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) invites its shareholders to partic...
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
Access Benjamin Graham's value investing criteria, intrinsic value calculations, and margin of safety analysis
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
Access detailed profitability metrics with visual gauges and benchmarks
Access detailed analysis of profitability strengths and positive performance indicators
Upgrade to PremiumAccess detailed analysis of profitability weaknesses and areas of concern
Upgrade to PremiumFinancial health metrics assess a company's ability to meet its financial obligations and its overall financial stability.
Access detailed financial health metrics with visual gauges and risk assessments
Access detailed analysis of financial health strengths and stability indicators
Upgrade to PremiumAccess detailed analysis of financial health weaknesses and risk factors
Upgrade to PremiumMeeting Expectations
Higher values indicate better execution and credibility
Recent Results
View complete earnings history and detailed performance analysis
Upgrade to PremiumEPS
Revenue
Insider trading data shows purchase and sale activities by company executives and board members.
Insider trading patterns can provide insights into how company executives and board members view the stock's future prospects.
Get complete insider sentiment analysis with detailed trading patterns, sentiment indicators, and trend insights